Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma.

Elizabeth A Kelly Stephane EsnaultLin Ying LiuMichael D Evans Mats W Johansson Sameer K MathurDeane F MosherLoren C DenlingerNizar N Jarjour

Published in: American journal of respiratory and critical care medicine (2017)

Mepolizumab reduced airway eosinophil numbers but had a limited effect on airway eosinophil activation markers, suggesting that these cells retain functionality. This observation may explain why IL-5 neutralization reduces but does not completely eradicate asthma exacerbations. Clinical trial registered with www.clinicaltrials.gov (NCT00802438).

Keyphrases

chronic obstructive pulmonary disease
clinical trial
lung function
induced apoptosis
cystic fibrosis
allergic rhinitis
cell cycle arrest
open label
phase ii
chronic rhinosinusitis